Jul 10, 2020
The Postpartum Depression Market Size in the 7MM was estimated to be USD 138.75 Million in 2017 and is expected to grow further with rise in PPD prevalence and immense opportunities with only a single marketed therapy available. Depression is one of the most common complications of pregnancy. During or after p...
Read More...
Jul 09, 2020
Sanofi licenses NK cells of Kiadis to boost the efficacy Sanofi has licensed the natural killer (NK) cells from Kiadis Pharma for use in combination with its multiple myeloma drug Sarclisa. The deal worth of USD 986 million gives the global rights to Sanofi for therapies that could lessen an efficacy-limit...
Read More...
Jul 08, 2020
Coronavirus pandemic has infected over 10 million people worldwide with over half a million casualties. The lock-down and other restriction measures such as social distancing have somehow slowed down the virus spread initially. But these steps have caused many serious humanitarian and economic consequences. Countri...
Read More...
Jul 07, 2020
Regeneron Pharmaceuticals launches the Phase III trials of REGN-COV2 for treatment and prevention of COVID-19. Regeneron is running two trials simultaneously, one for prevention and other for treatment, with the U.S. National Institute of Allergy and Infectious Diseases (NIAID). Phase III trial is studyi...
Read More...
Jul 06, 2020
The Nontuberculous mycobacterial infection market worth is expected to grow at a CAGR of 6.6% by 2030 owing to robust NTM infection pipeline, rising prevalence among immunocompromised as well as immunocompetent populations, and a considerable shift towards branded therapeutics options. Planet Earth hosts a dive...
Read More...
Jul 03, 2020
As per DelveInsight, the Small cell lung cancer market size is expected to increase at a CAGR of 15.2% during the study period (2017–30) attributing to a rich pipeline, healthcare spending, improved R&D, and discovery of novel targets. Small cell lung cancer (SCLC) or Small cell lung carcinoma is an aggressi...
Read More...
Jul 02, 2020
Amylyx Pharmaceuticals grabs USD 30 Million Amylyx Pharmaceuticals has grabbed USD 30 million boosts after posting positive data, which showed it could help decrease amyotrophic lateral sclerosis (ALS). AMX0035, which is its leading candidate, is being tested in degenerative ALS and Alzheimer’s disease....
Read More...
Jul 01, 2020
Over the past few decades Cancer has emerged as a major public health concern worldwide. Cancer is the second leading cause of deaths that takes place worldwide. Every sixth death is due to cancer, and in 2018 was estimated to be responsible for 9.6 million deaths. Costing people quality of lives and eventually lea...
Read More...
Jun 30, 2020
Intercept Pharmaceuticals receives a clear rejection from the FDA for its NASH drug, Obeticholic acid (OCA) Intercept Pharmaceuticals announced the issuance of a Complete Response Letter (CRL) by the FDA regarding the New Drug Application (NDA) for Obeticholic acid (OCA) for the treatment of fibrosis due to ...
Read More...
Aug 20, 2024
Sarepta Therapeutics, a leader in precision genetic medicine for rare diseases, has recently achieved a significant milestone with the FDA's approval of AMONDYS 45 (casimersen). This antisense oligonucleotide, developed from Sarepta’s phosphorodiamidate morpholino oligomer (PMO) platform, is now approved for treati...
Read More...